Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

NCT02035124 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study withdrawn due to slow accrual. No patients were enrolled.

Conditions

Advanced Prostate Cancer

Interventions

DRUG: BKM 120
DRUG: Cabazitaxel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]